Compare FINV & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FINV | DBVT |
|---|---|---|
| Founded | 2007 | 2002 |
| Country | China | France |
| Employees | N/A | 90 |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 948.8M |
| IPO Year | 2017 | 2014 |
| Metric | FINV | DBVT |
|---|---|---|
| Price | $4.73 | $13.82 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | $12.10 | ★ $32.04 |
| AVG Volume (30 Days) | ★ 517.5K | 275.2K |
| Earning Date | 05-19-2026 | 05-12-2026 |
| Dividend Yield | ★ 6.09% | N/A |
| EPS Growth | N/A | ★ 10.26 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,636,000.00 |
| Revenue This Year | N/A | $35.04 |
| Revenue Next Year | $10.58 | $2,360.78 |
| P/E Ratio | $3.87 | ★ N/A |
| Revenue Growth | N/A | ★ 35.77 |
| 52 Week Low | $4.35 | $8.51 |
| 52 Week High | $9.73 | $26.19 |
| Indicator | FINV | DBVT |
|---|---|---|
| Relative Strength Index (RSI) | 51.34 | 29.47 |
| Support Level | $4.55 | $12.63 |
| Resistance Level | $5.23 | $14.68 |
| Average True Range (ATR) | 0.13 | 0.86 |
| MACD | 0.02 | -0.20 |
| Stochastic Oscillator | 72.73 | 1.49 |
FinVolution Group is a provider of online consumer finance in China. The company offers various loan products, making financial services available to borrowers anytime, anywhere; designs a loan transaction process, and offers tailored risk-based pricing. It offers short-term loans to borrowers to meet immediate credit needs while allowing them to gradually establish their credit history through activities on the company's platform. The company generates revenues from fees charged to borrowers. The Group's long-lived assets are located in the PRC, and its revenues are derived from within the PRC.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.